Star Bulk Carriers Corp. (NASDAQ:SBLK) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -4.66% to $8.79. Star Bulk Carriers Corp. (NASDAQ:SBLK) reported that execution of contracts with affiliates of Oaktree Capital Management, L.P. and Senator Investment Group LP to sell Oaktree and Senator an aggregate of 6,310,272 of its common shares, at a purchase price of $8.154 per share.
The private placement, which is slated to close by early February 2017, is expected to result in aggregate gross proceeds to Star Bulk of approximately $51.5 million. The Company has agreed to grant shelf registration rights to the investors for the resale of their common shares.
Star Bulk intends to use the net proceeds of the offering for general corporate purposes. Giving effect to this offering, Oaktree and Senator are expected to beneficially own approximately 51.4% and 6.5%, respectively, of the Company’s outstanding common shares. The share price of SBLK attracts active investors, as stock price of week volatility recorded 12.35%. The stock is going forward to its 52-week low with 350.77% and lagging behind from its 52-week high price with -7.47%.
Inovalon Holdings, Inc. (NASDAQ:INOV) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.44% to close at $11.30 with the total traded volume of 13531 shares. Inovalon (INOV) reported that it has entered into an contract with Boehringer Ingelheim Pharmaceuticals Inc., a research-based, global pharmaceutical company, on behalf of Boehringer Ingelheim’s diabetes alliance with Eli Lilly and Company (LLY).
The contract utilizes Inovalon and Avalere’s combined breadth of healthcare capabilities and integrated platform supporting greater consumer insight, data integration and analytics and integrated provider and patient-level intervention capabilities. This will support outcomes-based contracting and help translate clinical outcomes into real world practice to ultimately improve patient clinical care.
“The Boehringer Ingelheim and Lilly diabetes alliance is committed to innovation through the discovery and development of treatment options where unmet needs exist, as illustrated by the breakthrough evidence from the landmark EMPA-REG OUTCOME® trial which evaluated cardiovascular outcomes in adults with type 2 diabetes,” said Christine Marsh, vice president, Market Access, Boehringer Ingelheim Pharmaceuticals, Inc. The firm has institutional ownership of 62.90%, while insider ownership included 1.30%. Its price to sales ratio ended at 3.71. INOV attains analyst recommendation of 3.20 with week performance of 1.34%.